Expansion of NCI-sponsored clinical research in hematologic malignancies to Brooklyn and Queens - The Meyer Cancer Center (MCC) at Weill Cornell Medicine and NewYork-Presbyterian serves a large population across Manhattan, Brooklyn, and Queens, a catchment area of six million. This region faces poor cancer outcomes, with significant unmet needs in Brooklyn and Queens. Through the One MCC initiative, the center integrates interdisciplinary research to address these issues, advancing cancer prevention, treatment, and educational outreach. The MCC's Cancer Clinical Trials Office (CCTO) oversees 200+ trials across the National Clinical Trials Network (Alliance, NRG, COG), Experimental Therapeutics Clinical Trials Network, and other sponsors, supporting over 550 annual enrollees. Dr. Peter Martin focuses on caring for patients with lymphoma, with clinical practices in Manhattan and Brooklyn. An experienced clinical and translational researcher, Dr. Martin is a productive member of the Alliance Lymphoma Committee and NCI Lymphoma Steering Committee. He has led and contributed to multiple NCTN trials, and his investigator-initiated research has provided the framework for larger trials within the Alliance. Further advancing MCC’s mission, the Dr. Martin collaborates with organizations to promote patient education around hematological malignancies and clinical research. He is actively engaged with MCC's Office of Community Outreach and Engagement and Research Informatics team with the objective of increasing accessibility to clinical research. Moreover, he will continue collaborations with population scientists at WCM and through the NCI-funded Lymphoma Epidemiology of Outcomes cohort study to better understand barriers to research participation and to develop strategies to overcome them.
